andrew balo  dexcom inc  zoominfocom dexcom leadership  andrew k balo  dexcom error fb gplus in twitter downarrow email phone checkmark padlock circlearrow minus plus playbtn close clipboardicon shoppingcarticon speechbubbleicon stethoscopeicon pharmacists menu logo leftarrow rightarrow facebook search cart providers payers my account united states go back australia bahrain belgien belgique belgië canada canada français chile colombia danmark deutschland españa france hong kong india ireland italia kuwait lebanon luxembourg magyarország nederlands new zealand norge oman polska portugal qatar saudi arabia schweiz slovenia slovenská republika south africa suisse suomi sverige svizzera türkiye united arab emirates united kingdom united states österreich česká republika ישראל order search form search leadership dexcom leadership  andrew k balo executive vice president – clinical regulatory  global access andrew k balo giving people with diabetes the tools and technology to improve their care and quality of life andy balo is executive vice president of clinical regulatory and global access at dexcom andy was part of the original executive team at dexcom playing a critical role in shaping the future of the company currently he is responsible for regulatory submissions and clinical trials worldwide he also coordinates quality activities in multiple dexcom manufacturing facilities to meet fda compliance regulations and guidelines joining dexcom in  andy has initiated all clinical trials performed at dexcom as well as all us and ous regulatory submissions totaling  submissions he is widely regarded as an industry expert in regulatory and clinical strategies and previously sat on several fda panels including cardiovascular neurological and gastrointestinal andy has been instrumental in bringing several breakthrough medical devices to market including a neurological cooling device mechanical and tissuebased heart valves pacemakers pacing leads aortic grafts and d electrophysiology mapping devices and has obtained approval for over  pmas and pma supplements prior to joining dexcom andy served as vice president of regulatory and clinical affairs for innercool therapies and endocardial solutions during the s andy held several positions at st jude medical including vice president regulatory clinical and technical services and corporate vice president quality regulatory and clinical affairs and was an officer of the company  andy received his bachelor of science degree in microbiology and chemistry from the university of maryland and completed graduate studies at ucla and stanford dexcom inc dxcm upgraded to “buy” at bidaskclub  american banking news home get email updates about disclaimer contact privacy policy   business news us news world news stock ratings analysts upgrades analysts downgrades analysts eps estimates analysts price targets analysts new coverage corporate earnings earnings results earnings guidance earnings previews dividends insider trades options press releases dexcom inc  get news  ratings daily enter your email address below to get the latest news and analysts ratings for dexcom inc with our free daily email newsletter recent stories rowan companies plc rdc stock rating upgraded by seaport global securities hooker furniture corporation hoft vs tempur sealy international tpx financial survey critical review moelis  mc versus pjt partners pjt reviewing sony corp ord sne and nortek ntk reviewing helen of troy limited hele  lifetime brands lcut q  earnings estimate for eog resources inc issued by jefferies group eog quad graphics quad  arc document solutions nysearc critical comparison analyzing steelcase scs and cott corporation cot energizer holdings inc nyseepc expected to earn q  earnings of  per share boise cascade llc bcc and deltic timber corporation del financial comparison best buy co bby versus aaron’s aan critical contrast analyzing summer infant nasdaqsumr  mattel mat dreamworks animation nasdaqdwa versus time warner twx head to head contrast analysts anticipate atmos energy corporation ato to announce  earnings per share head to head review cai international cap vs navios maritime acquisition corporation nysenna  earnings per share expected for gentherm inc nasdaqthrm this quarter red lion hotels corporation nyserlh receives average rating of “strong buy” from analysts kalobios pharmaceuticals inc kbio receives consensus recommendation of “” from analysts critical comparison neonode neon and fabrinet nysefn clorox company the clx and wd wdfc critical analysis dexcom inc dxcm upgraded to “buy” at bidaskclub june st  •  comments • filed under • by abmn staff filed under analysts upgrades • market news tweet dexcom inc nasdaqdxcm was upgraded by investment analysts at bidaskclub from a “hold” rating to a “buy” rating in a note issued to investors on wednesday a number of other brokerages have also recently issued reports on dxcm b riley reiterated a “buy” rating and set a  target price on shares of dexcom in a research report on thursday april th oppenheimer holdings inc set a  price objective on shares of dexcom and gave the company a “buy” rating in a research report on wednesday march st northcoast research restated a “buy” rating on shares of dexcom in a research report on wednesday march st btig research cut shares of dexcom from a “buy” rating to a “neutral” rating in a research report on wednesday may rd finally william blair restated an “outperform” rating on shares of dexcom in a research report on thursday april th four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock the company has a consensus rating of “buy” and a consensus target price of  get dexcom inc alerts shares of dexcom nasdaqdxcm traded up  during trading on wednesday hitting  the company’s stock had a trading volume of  shares dexcom has a  week low of  and a  week high of  the firm’s  day moving average price is  and its day moving average price is  the company’s market cap is  billion dexcom nasdaqdxcm last announced its earnings results on tuesday may nd the medical device company reported  earnings per share eps for the quarter topping analysts’ consensus estimates of  by  the business had revenue of  million during the quarter compared to analysts’ expectations of  million dexcom had a negative net margin of  and a negative return on equity of  on average analysts predict that dexcom will post  earnings per share for the current year trademark violation notice this piece was first posted by american banking news and is owned by of american banking news if you are accessing this piece on another domain it was copied illegally and reposted in violation of us  international copyright laws the correct version of this piece can be read at httpswwwamericanbankingnewscomdexcomincdxcmupgradedtobuyatbidaskclubhtml in related news insider terrance h gregg sold  shares of dexcom stock in a transaction that occurred on thursday april th the shares were sold at an average price of  for a total transaction of  following the transaction the insider now owns  shares of the company’s stock valued at approximately  the transaction was disclosed in a legal filing with the securities  exchange commission which can be accessed through this hyperlink also ceo kevin r sayer sold  shares of dexcom stock in a transaction that occurred on monday april th the stock was sold at an average price of  for a total transaction of  following the transaction the chief executive officer now directly owns  shares in the company valued at approximately  the disclosure for this sale can be found here insiders have sold a total of  shares of company stock worth  in the last three months  of the stock is owned by insiders a number of hedge funds and other institutional investors have recently made changes to their positions in dxcm russell investments group ltd bought a new position in shares of dexcom during the fourth quarter worth  state board of administration of florida retirement system raised its position in shares of dexcom by  in the fourth quarter state board of administration of florida retirement system now owns  shares of the medical device company’s stock worth  after buying an additional  shares during the last quarter comerica bank raised its position in shares of dexcom by  in the fourth quarter comerica bank now owns  shares of the medical device company’s stock worth  after buying an additional  shares during the last quarter state street corp raised its position in shares of dexcom by  in the fourth quarter state street corp now owns  shares of the medical device company’s stock worth  after buying an additional  shares during the last quarter finally raymond james financial services advisors inc raised its position in shares of dexcom by  in the fourth quarter raymond james financial services advisors inc now owns  shares of the medical device company’s stock worth  after buying an additional  shares during the last quarter about dexcom dexcom inc dexcom is a medical device company the company is focused on the design development and commercialization of continuous glucose monitoring cgm systems for ambulatory use by people with diabetes and for use by healthcare providers the company’s products consist of dexcom g platinum and dexcom g mobile receive news  ratings for dexcom inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for dexcom inc and related companies with marketbeatcoms free daily email newsletter leave a reply click here to cancel reply name required mail will not be published required website wordpress hashcash needs javascript to work but your browser has javascript disabled your comment will be placed in moderation  copyright american banking and market news  all rights reserved privacy policy and disclosures  about  advertising  contact content on this website is not meant to be a recommendation or an offer to buy or sell any security click here to read our full disclaimer andrew k balo dexcom inc svp clinical  regulatory affairs  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   andrew k balo svp clinical  regulatory affairs dexcom inc email realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for andrew k balo at dexcom inc andrew k balo works as svp clinical  regulatory affairs  dexcom inc is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more leads or mediamarketing prospecting automation start a free trial now recent related news  the dexcom dxcm receives daily media sentiment rating of  these are some of the headlines that may have impacted accern’s scoring media headlines about dexcom nasdaqdxcm have been trending very positive on monday according to accern sentiment analysis the research firm identifies positive and negative news coverage by analyzing more than  million blog and news sources in realtime accern ranks coverage of publiclytraded companies on a scale of negative one to one with scores closest to one being the most favorable dexcom earned a media sentiment score of  on accern’s scale  people in this article andrew k balo  somewhat positive press coverage somewhat unlikely to affect dexcom nasdaqdxcm share price news headlines about dexcom nasdaqdxcm have been trending somewhat positive recently according to accern sentiment analysis accern scores the sentiment of news coverage by reviewing more than  million news and blog sources in real time accern ranks coverage of public companies on a scale of negative one to positive one with scores nearest to one being the most favorable dexcom earned a news sentiment score of  on accern’s scale  people in this article andrew k balo learn more about andrew k balo and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about andrew k balo and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved dxcm andrew k balo insider trades for dexcom inc bulletin sports retailer hibbett warns on profit amid very challenging sales trends » webmd sold to kkr for share—shares halted after  premarket jump » investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close dexcom inc nasdaq dxcm go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus dexcom inc after hours  quotes are delayed by  min jul    pm dxcm quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual andrew k balo mr andrew k balo is evpclinical regulatory affairs  quality at dexcom inc mr balo was previously employed as vice presidentregulatory  clinical affairs by innercool therapies inc vpquality regulatory  clinical affairs by st jude medical inc and vice presidentrgulatory  clinical affairs by endocardial solutions inc he received his undergraduate degree from the university of maryland transactions date shares transaction value     disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share                     disposition at  per share      award at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share                disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share                     award at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share                disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share           disposition at  per share      derivativenonderivative trans at  per share                award at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share           disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share           disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share           disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share           derivativenonderivative trans at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share           disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share           award at  per share      disposition at  per share      disposition at  per share       copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr terrance h gregg executive chairman mr kevin ronald sayer president chief executive officer  director mr jeffrey c moy senior vice presidentoperations mr kevin sun chief financial officer  vice president mr jacob leach senior vice presidentresearch  development mr donald abbey executive vpquality  information technology dr claudia graham vice presidentglobal access mr richard b doubleday chief commercial officer  executive vp mr timothy f obrien directorlegal affairs mr john d lister general managercommercial operations mr steven robert pacelli executive vpstrategy  corporate development ms heather ace senior vice presidenthuman resources mr andrew k balo evpclinical regulatory affairs  quality mr richard alexander collins independent director mr mark g foletta lead independent director mr steven r altman independent director dr jay s skyler independent director dr eric j topol independent director dr barbara e kahn independent director mr nicholas augustinos independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aalphabet earnings a  billion hit for google potential youtube results for investors agilead stock surges  on latestage hiv trial results agilead sciences says latestage results for hiv drug combination are similar to standard of care akkrs stock jumps  premarket after webmd buyout deal avf corp shares up  premarket ahasbro stock down  premarket abmw denies claims that german car makers may have operated a cartel adollar edges higher recovering slightly from recent slide ahead of fed meeting ahibbett sports issues profit warning citing very challenging sales trends aapplied materials announces new cfo awebmd to be bought by kkrs internet brands for  billion ablue apron shares up  in premarket trade ablue apron initiated at buy  price target at suntrust robinson humphrey ablue apron initiated at outperform  price target at rbc capital markets ahibbett sports announces launch of new ecommerce site ahibbett sports cites very challenging sales trends for q loss ahibbett sport current q factset consensus eps  cents ahibbett sports sees q loss  cents to  cents ahibbett warns that q samestore sales likely to fall  ahibbett sports stock halted for news loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  ﻿ dexcom inc dxcm evp sells  in stock  bnb daily daily ratings  news for dexcom inc complete the form below to receive the latest headlines and analysts recommendationsfor dexcom inc with our free daily email newsletter follow bnbdailynews recent posts booker group plc lonbok earns sell rating from shore capital topps tiles plc lontpt price target lowered to gbx  at peel hunt fortress biotech inc fbio given a  price target at hc wainwright cyberark software ltd cybr rating lowered to buy at bidaskclub bellicum pharmaceuticals inc nasdaqblcm insider sells  in stock mitchells  butlers plc lonmab coverage initiated by analysts at liberum capital ssp group plc lonsspg now covered by analysts at liberum capital dexcom inc dxcm evp sells  in stock international speedway corporation nasdaqisca director hyatt j brown purchases  shares palo alto networks inc panw director james j goetz sells  shares midamerica apartment communities inc forecasted to post fy earnings of  per share maa bidaskclub upgrades ceco environmental corp cece to hold kbr inc nysekbr receives average recommendation of “hold” from analysts franklin resources inc ben expected to post earnings of  per share nbt bancorp inc nasdaqnbtb rating lowered to sell at bidaskclub bunge limited bg downgraded by zacks investment research charles river laboratories international inc crl upgraded by zacks investment research to “buy” qiwi plc nasdaqqiwi downgraded by bidaskclub illumina inc nasdaqilmn insider michel bouchard sells  shares care capital properties inc nyseccp upgraded at bidaskclub dexcom inc dxcm evp sells  in stock posted by dan jones on jul rd   no comments dexcom inc nasdaqdxcm evp andrew k balo sold  shares of the firm’s stock in a transaction dated monday july th the shares were sold at an average price of  for a total value of  the transaction was disclosed in a legal filing with the securities  exchange commission which can be accessed through this link andrew k balo also recently made the following trades get dexcom inc alerts on monday june th andrew k balo sold  shares of dexcom stock the shares were sold at an average price of  for a total value of  on wednesday may th andrew k balo sold  shares of dexcom stock the shares were sold at an average price of  for a total value of  dexcom inc nasdaqdxcm traded down  during trading on friday reaching  the company had a trading volume of  shares the company’s market capitalization is  billion dexcom inc has a one year low of  and a one year high of  the firm’s  day moving average is  and its  day moving average is  dexcom nasdaqdxcm last announced its quarterly earnings data on tuesday may nd the medical device company reported  earnings per share eps for the quarter topping the consensus estimate of  by  dexcom had a negative return on equity of  and a negative net margin of  the company had revenue of  million for the quarter compared to analysts’ expectations of  million on average equities research analysts predict that dexcom inc will post  earnings per share for the current year illegal activity notice “dexcom inc dxcm evp sells  in stock” was first posted by bnb daily and is the sole property of of bnb daily if you are reading this article on another publication it was illegally copied and reposted in violation of us  international trademark and copyright legislation the legal version of this article can be viewed at httpswwwbaseballnewsblogcomdexcomincdxcmevpandrewkbalosellssharesupdatedhtml a number of hedge funds and other institutional investors have recently made changes to their positions in dxcm blackrock inc boosted its position in shares of dexcom by  in the first quarter blackrock inc now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the period bank of new york mellon corp boosted its position in shares of dexcom by  in the first quarter bank of new york mellon corp now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the period fmr llc boosted its position in shares of dexcom by  in the first quarter fmr llc now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the period norges bank purchased a new position in shares of dexcom during the fourth quarter valued at about  finally janus capital management llc boosted its position in shares of dexcom by  in the first quarter janus capital management llc now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the period dxcm has been the topic of several recent analyst reports cowen and company reaffirmed an “outperform” rating and issued a  price target on shares of dexcom in a report on tuesday april th btig research cut dexcom from a “buy” rating to a “neutral” rating in a report on wednesday may rd william blair reissued an “outperform” rating on shares of dexcom in a report on thursday april th jefferies group llc decreased their price objective on dexcom to  and set a “buy” rating on the stock in a report on tuesday may th finally bidaskclub raised dexcom from a “hold” rating to a “buy” rating in a report on wednesday june st five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock the stock currently has an average rating of “buy” and an average price target of  about dexcom dexcom inc dexcom is a medical device company the company is focused on the design development and commercialization of continuous glucose monitoring cgm systems for ambulatory use by people with diabetes and for use by healthcare providers the company’s products consist of dexcom g platinum and dexcom g mobile receive news  ratings for dexcom inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for dexcom inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website ﻿ dexcom inc nasdaqdxcm evp andrew k balo sells  shares  chaffey breeze daily ratings  news for dexcom inc complete the form below to receive the latest headlines and analysts recommendationsfor dexcom inc with our free daily email newsletter follow chaffeybreeze recent posts comparing image sensing systems nasdaqisns  mesa laboratories mlab analyzing renewable energy group nasdaqregi  enviva partners eva  eps expected for pharmerica corporation nysepmc this quarter liberty interactive corporation nasdaqqvca expected to announce earnings of  per share entertainment one ltd loneto given consensus rating of “buy” by brokerages eqt midstream partners lp eqm pt set at  by scotiabank wells fargo  company reiterates “buy” rating for amphastar pharmaceuticals inc nasdaqamph westpac banking corporation nysewbk upgraded by zacks investment research to “buy” the dixie group inc nasdaqdxyn to release quarterly earnings on tuesday wabash national corporation nysewnc to release quarterly earnings on tuesday zacks investment research downgrades tenaris sa ts to hold discover financial services dfs position increased by continental advisors llc  shares in twentyfirst century fox inc foxa acquired by ballentine partners llc tabula rasa healthcare inc trhc now covered by chardan capital wr berkley corporation wrb to post q  earnings of  per share langen mcalenn forecasts canadian western bank tsecwb receives c average price target from brokerages watsco inc wso set to announce earnings on tuesday plains all american pipeline lp paa given a  price target by scotiabank analysts yingli green energy holding company limited yge stock rating reaffirmed by axiom securities lincoln educational services corporation linc stock rating upgraded by zacks investment research dexcom inc nasdaqdxcm evp andrew k balo sells  shares posted by charlotte bryant on jul th   no comments dexcom inc nasdaqdxcm evp andrew k balo sold  shares of dexcom stock in a transaction on monday june th the shares were sold at an average price of  for a total value of  the transaction was disclosed in a document filed with the sec which is available through the sec website andrew k balo also recently made the following trades get dexcom inc alerts on monday july th andrew k balo sold  shares of dexcom stock the shares were sold at an average price of  for a total value of  on wednesday may th andrew k balo sold  shares of dexcom stock the shares were sold at an average price of  for a total value of  on monday april th andrew k balo sold  shares of dexcom stock the shares were sold at an average price of  for a total value of  dexcom inc nasdaq dxcm opened at  on friday the firm’s market cap is  billion dexcom inc has a week low of  and a week high of  the company’s  day moving average price is  and its  day moving average price is  dexcom nasdaqdxcm last issued its quarterly earnings data on tuesday may nd the medical device company reported  earnings per share eps for the quarter topping the thomson reuters’ consensus estimate of  by  the firm had revenue of  million during the quarter compared to the consensus estimate of  million dexcom had a negative net margin of  and a negative return on equity of  analysts predict that dexcom inc will post  earnings per share for the current fiscal year copyright violation warning this article was published by chaffey breeze and is the property of of chaffey breeze if you are accessing this article on another domain it was stolen and republished in violation of us and international trademark  copyright legislation the correct version of this article can be accessed at httpswwwchaffeybreezecomdexcomincnasdaqdxcmevpandrewkbalosellsshareshtml a number of analysts recently issued reports on dxcm shares b riley reissued a “buy” rating and set a  price objective on shares of dexcom in a research report on thursday april th bidaskclub cut dexcom from a “buy” rating to a “hold” rating in a research report on wednesday july th bmo capital markets reaffirmed a “buy” rating and issued a  price target on shares of dexcom in a research report on thursday btig research cut dexcom from a “buy” rating to a “neutral” rating in a research report on wednesday may rd finally william blair reaffirmed an “outperform” rating on shares of dexcom in a research report on thursday april th five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock the company currently has a consensus rating of “buy” and an average price target of  a number of large investors have recently modified their holdings of dxcm blackrock inc increased its stake in shares of dexcom by  in the first quarter blackrock inc now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the period bank of new york mellon corp increased its stake in shares of dexcom by  in the first quarter bank of new york mellon corp now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the period janus capital management llc increased its stake in shares of dexcom by  in the fourth quarter janus capital management llc now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the period brown advisory inc increased its stake in shares of dexcom by  in the fourth quarter brown advisory inc now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the period finally fmr llc increased its stake in shares of dexcom by  in the first quarter fmr llc now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the period about dexcom dexcom inc dexcom is a medical device company the company is focused on the design development and commercialization of continuous glucose monitoring cgm systems for ambulatory use by people with diabetes and for use by healthcare providers the company’s products consist of dexcom g platinum and dexcom g mobile receive news  ratings for dexcom inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for dexcom inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website ﻿ dexcom inc dxcm raised to “hold” at zacks investment research  markets daily daily ratings  news for dexcom inc complete the form below to receive the latest headlines and analysts recommendationsfor dexcom inc with our free daily email newsletter follow themarketsdaily the markets daily recent posts dexcom inc dxcm raised to “hold” at zacks investment research ambarella inc amba shares bought by van berkom  associates inc adtran inc adtn shares bought by van berkom  associates inc tesoro logistics lp tllp plans dividend increase –  per share synovus financial corp nysesnv shares sold by prospera financial services inc apple inc nasdaqaapl position lowered by horan capital management real goods solar nasdaqrgse  masonite international corporation door critical contrast saexploration holdings saex and forbes energy services nasdaqfes headtohead analysis reviewing cosi cosi  rci hospitality holdings rick reviewing sterling construction nasdaqstrl  jacobs engineering group jec regeneron pharmaceuticals inc nasdaqregn stock rating reaffirmed by bank of america corporation somewhat favorable news coverage somewhat unlikely to impact sabine oil  gas corp fst share price sapient corp sape given daily news sentiment score of  somewhat positive press coverage somewhat unlikely to affect gfi group gfig share price williams companies inc the wmb shares bought by state treasurer state of michigan lyondellbasell industries nv lyb shares bought by state treasurer state of michigan prospera financial services inc takes position in united therapeutics corporation nasdaquthr cme group inc cme shares bought by bedrijfstakpensioenfonds voor de media pno diversified trust co has  stake in texas capital bancshares inc nasdaqtcbi dexcom inc dxcm raised to “hold” at zacks investment research posted by tristan rich on jul st   no comments zacks investment research upgraded shares of dexcom inc nasdaqdxcm from a sell rating to a hold rating in a research note published on tuesday according to zacks “in the past one year dexcom has underperformed the broader industry in terms of price furthermore a disappointing estimate revision trend indicates looming concerns ahead dexcom reported narrowerthanexpected loss in the first quarter we believe the company’s margins will continue to be under pressure in the coming quarters owing to high product development costs and rising expenditures on research  development specifically the company is expected to have lower margins on transmitter sales in spite of the cost reduction initiatives additionally cutthroat competition in the market for blood glucose monitoring devices is a major headwind on the positive side the glucose monitoring market represents significant commercial opportunity for dexcom the company has also signed collaborative agreements with several companies which should not only bring in cash but also help expand its product portfolio” get dexcom inc alerts dxcm has been the subject of several other reports oppenheimer holdings inc reaffirmed a buy rating on shares of dexcom in a research note on wednesday march nd canaccord genuity reaffirmed a buy rating and issued a  target price on shares of dexcom in a research note on wednesday june th piper jaffray companies reaffirmed an overweight rating and issued a  target price on shares of dexcom in a research note on monday may nd bidaskclub raised shares of dexcom from a hold rating to a buy rating in a research note on wednesday june st finally btig research cut shares of dexcom from a buy rating to a neutral rating in a research note on wednesday may rd five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock the stock presently has an average rating of buy and a consensus price target of  shares of dexcom dxcm traded down  on tuesday reaching  the company had a trading volume of  shares the firm’s market capitalization is  billion dexcom has a year low of  and a year high of  the firm has a day moving average price of  and a  day moving average price of  dexcom nasdaqdxcm last released its earnings results on tuesday may nd the medical device company reported  eps for the quarter topping the thomson reuters’ consensus estimate of  by  the firm had revenue of  million during the quarter compared to analysts’ expectations of  million dexcom had a negative net margin of  and a negative return on equity of  equities research analysts predict that dexcom will post  earnings per share for the current year warning this piece was posted by markets daily and is the property of of markets daily if you are accessing this piece on another website it was illegally stolen and reposted in violation of united states  international trademark  copyright law the legal version of this piece can be accessed at httpswwwthemarketsdailycomdexcomincdxcmraisedtoholdatzacksinvestmentresearchhtml in related news evp steven robert pacelli sold  shares of dexcom stock in a transaction on friday june rd the shares were sold at an average price of  for a total transaction of  the transaction was disclosed in a document filed with the sec which is accessible through this hyperlink also evp richard doubleday sold  shares of dexcom stock in a transaction on monday april th the shares were sold at an average price of  for a total transaction of  following the transaction the executive vice president now owns  shares in the company valued at approximately  the disclosure for this sale can be found here insiders have sold a total of  shares of company stock worth  in the last  days company insiders own  of the company’s stock institutional investors have recently bought and sold shares of the stock fmr llc raised its position in dexcom by  in the first quarter fmr llc now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the last quarter vanguard group inc raised its position in shares of dexcom by  in the first quarter vanguard group inc now owns  shares of the medical device company’s stock worth  after buying an additional  shares in the last quarter baillie gifford  co raised its position in shares of dexcom by  in the first quarter baillie gifford  co now owns  shares of the medical device company’s stock worth  after buying an additional  shares in the last quarter blackrock inc raised its position in shares of dexcom by  in the first quarter blackrock inc now owns  shares of the medical device company’s stock worth  after buying an additional  shares in the last quarter finally janus capital management llc raised its position in shares of dexcom by  in the first quarter janus capital management llc now owns  shares of the medical device company’s stock worth  after buying an additional  shares in the last quarter about dexcom dexcom inc dexcom is a medical device company the company is focused on the design development and commercialization of continuous glucose monitoring cgm systems for ambulatory use by people with diabetes and for use by healthcare providers the company’s products consist of dexcom g platinum and dexcom g mobile get a free copy of the zacks research report on dexcom dxcm for more information about research offerings from zacks investment research visit zackscom receive news  ratings for dexcom inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for dexcom inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website andrew balo dexcom inc profile  biography  bloomberg feedback andrew balo exec vpclinical dexcom inc career history exec vpclinical dexcom inc present senior vpclinical  regulatory dexcom inc  vpclinical  regulatory dexcom inc  vpregulatory  clinical innercool therapies inc  show more website wwwdexcomcom corporate information address  sequence drive san diego ca  united states phone  fax  web url wwwdexcomcom from the web personal information education university of maryland bachelors degree university of california san francisco foundation graduated stanford university graduated show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data andrew balos phone  address  peoplebyname contact login home people alphabetically b balo andrew balo people directory with over  names record id andrew balo cedar lake pkwyminneapolis mn  background check  available record id andrew balo petree stel cajon ca  background check  available record id andrew balo leander stpittsburgh pa  background check  available record id andrew k balo de la osa stwoodland hills ca  background check  available record id andrew k balo hillcrest drthousand oaks ca  background check  available record id andrew k balo craven ridge waysan diego ca age  born jan  background check  available record id andrew k balo avenida castanacarlsbad ca age  born jan  background check  available record id andrew k balo hunters glen drsan diego ca age  born jan  background check  available record id andrew f balo leslie rdel cajon ca background check  available record id andrew f balo golf glen drsan marcos ca background check  available      total records available tweet testimonials read testimonials from real customers who already used our services read more webmasters earn  commission on every sale you drive to our website weekly payouts read more mobile version visit us from your smart phone anywhere you are read more recent lookups check out the most recent reverse phone lookups on peoplebynamecom read more home mobile version phone directory people directory remove information terms of service privacy policy affiliate program about us member login frequently asked questions contact us testimonials careers product  services volume discounts site map  peoplebyname all rights reserved